Marinomed Biotech AG logo

MARI - Marinomed Biotech AG News Story

€124 -1.0  -0.8%

Last Trade - 07/05/21

Sector
Healthcare
Size
Small Cap
Market Cap £159.2m
Enterprise Value £162.3m
Revenue £7.07m
Position in Universe 662nd / 1050

BRIEF-Marinomed Biotech Completes Phase II Clinical Trial With Tacrosolv

Mon 12th April, 2021 6:47am
April 12 (Reuters) - MARINOMED BIOTECH AG  MARI.VI :
    * COMPLETES PHASE II CLINICAL TRIAL WITH TACROSOLV FOR THE
TREATMENT OF RHINOCONJUNCTIVITIS (ALLERGIC EYE INFLAMMATION)

Source text for Eikon:  ID:nEQ216KGSa 
Further company coverage:  MARI.VI 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.